People in the News

Jan 18, 2019

TJ Johnson, John Lubniewski

HTG Molecular Diagnostics has announced that TJ Johnson, the firm's current CEO, will assume the role of executive chairman of its board of directors. John Lubniewski, HTG's president and chief operating officer, will succeed Johnson as CEO. In addition, Ann Hanham will assume the role of lead independent director at the end of Q1 2019.

Lubniewski has served as HTG's president and COO since April 2018, joining the firm in 2011 as chief business officer. Before HTG, Lubniewski served in several leadership roles at Ventana, including senior VP and life cycle leader for platforms and clinical assays, as well as head of global marketing. Prior to Ventana, Lubniewski worked at Corning for over a decade in a variety of roles.

Jan 17, 2019

Deanna Church

Deanna Church has joined gene editing technology company Inscripta as senior director of mammalian applications. Previously, she was senior director of applications at 10x Genomics, and before that, senior director of genomics and content at Personalis. Prior to that, she was a staff scientist at the National Center for Biotechnology Information. Church holds a PhD in genomics, genetics, and molecular biology from the University of California, Irvine, and a BA in liberal arts from the University of Virginia.

Jan 14, 2019

Jonathan Jaglom, Gil Ronen

NRGene said this week that it has appointed Jonathan Jaglom as the firm's CEO. Jaglom succeeds NRGene's cofounder Gil Ronen, who has transitioned to the firm's president. Jaglom previously served as NRGene's chief operating officer. Prior to joining NRGene in 2018, Jaglom served as CEO of MakerBot. He has also held executive roles at Stratasys, including general manager and VP of sales operations. 

Jan 09, 2019

William Finger

Cancer Genetics has appointed William Finger as its executive VP of precision medicine and biopharma solutions. He will be responsible for developing and overseeing the company's precision medicine and biopharma and clinical trial business unit. Finger has more than 25 years of experience in the life sciences, diagnostics, and lab service industries. Before joining Cancer Genetics, he acted as managing director of precision medicine and diagnostics for Kineticos, a life science consultancy firm. Before Kineticos, Finger spent 12 years at Laboratory Corporation of America, where he held leadership positions in scientific affairs, preclinical services, biorepository, and operations.

Jan 08, 2019

Richard Compton

Richard Compton resigned as director of Metrichor, a sister company of Oxford Nanopore Technologies, last month. He was appointed to the firm's board in 2016 and was also general manager at Metrichor. Compton remains VP of commercial operations at Oxford Nanopore. He previously served as VP and general manager of the EMEA region at Illumina.

Jan 08, 2019

Ian Heynen

Ian Heynen has been named general manager of Sysmex Canada, a wholly owned subsidiary of Sysmex America. He will execute the firm's business strategy in the Canadian market and will report to Sysmex Canada CEO Andy Hay. Heynen was most recetly senior vice president of sales and marketing for Profound Medical. Prior to that he was acting president of the international division of Hologic. 

Jan 07, 2019

Samar Parikh

Binx Health has appointed Samar Parikh to its board of directors. Parikh has held various leadership positions at Amazon including global leader business development and strategy, and general manager CPG, consumer healthcare, and consumer healthcare innovation. Boston-based Binx is developing a desktop point-of-care platform called Io to perform rapid PCR-based detection in 30 minutes and with laboratory quality results. A multicenter, clinical study is currently underway to evaluate Io for clearance from the US Food and Drug Administration for chlamydia and gonorrhea. 

Jan 07, 2019

Cara Williams

Cara Williams has joined the scientific advisory board of data science company Genialis. She is vice president and head of immunology and respiratory disease research Germany at Boehringer Ingelheim. Prior to that, she was senior director of inflammation and remodeling research at Pfizer. Williams holds a PhD from Liverpool University.

Jan 07, 2019

Cindy Perettie

Foundation Medicine, a Roche company, has appointed Cindy Perettie as its CEO effective Feb. 4, replacing Troy Cox. Most recently, Perettie served as senior VP in global oncology product strategy at Roche's oncology unit. Prior to Roche, she acted as president of global development innovations at the Sarah Cannon Research Institute. Perettie has also held a number of positions at Genentech, also a unit of Roche, including VP of global regulatory operations and regional head of Europe, Middle East, and Africa operations and global development.

Jan 07, 2019

Jon Cohen, Geoff Monk

Jon Cohen has been appointed as executive chairman of BioReference Laboratories, a unit of Opko Health.

Most recently, he was senior vice president and group executive for diagnostic solutions at Quest Diagnostics. Prior to that, he was a managing director for health industries services at PricewaterhouseCoopers, and before that, chief medical officer at North Shore-Long Island Jewish Health System. Cohen holds a BS degree from the University of Miami and an MD degree from the University of Miami School of Medicine.

OpkoHealth has also promoted Geoff Monk to president of BioReference Laboratories. He joined the company last year as general manager.

Jan 04, 2019

Paul Meister

Arbor Biotechnologies has appointed Paul Meister to its board of directors. Meister serves as CEO of Liberty Lane Partners and previously served as president of MacAndrews & Forbes, CEO of inVentiv Health (now known as Syneos Health), and chairman of the board of Thermo Fisher Scientific and vice chairman of Fisher Scientific International, prior to Fisher's merger with Thermo.

Jan 04, 2019

Christine Tsingos

Christine Tsingos intends to retire as Executive Vice President and Chief Financial Officer of Bio-Rad, effective April 30, 2019. She has served as CFO for 16 years, during which time the company increased its revenues more than 240 percent and saw an appreciation in its stock price from approximately $30 to a recent high of more than $300 per share. Tsingos will remain in her current role through April 30, and will assist in the transition to a successor.

Jan 03, 2019

Clinton Musil

Clinton Musil has been appointed as chief business officer of Personalis, where he will initially focus on financing strategy. He joins the company from ARMO Biosciences. Prior to that, he was a managing director at Hercules Capital. Musil holds an MBA from Harvard Business School and a BS in molecular and cellular biology from the University of Arizona.

Jan 03, 2019

James Angus McDonald, Tim Cowper

James Angus McDonald has left the board of directors of Oxford Nanopore Technologies as well as the board of its daughter companies, the Genome Foundry and Metrichor, effective Dec. 13, 2018. He had been a director for Oxford Nanopore since 2010, for Metrichor since 2013, and for the Genome Foundry since 2015. McDonald was immediately replaced as director of all three companies by Tim Cowper, Oxford Nanopore's vice president of finance. Cowper joined the firm in 2012 and oversees its financial team and strategic supply chain operations. In addition, in November 2018, he was appointed as director of Oxford Nanopore Manufacturing, a new daughter company.

Jan 03, 2019

Betsy Hanna

Clinical Genomics has appointed Betsy Hanna as its president and CEO. In addition, she will join the firm's board of directors. Hanna succeeds Lawrence LaPointe as CEO, who will transition to the new role of chief innovation officer and serve as an advisor to the board. Hanna previously served as Clinical Genomics' chief commercial officer. Before that, she served as president and COO at Origin. Prior to Origin, Hanna held leadership positions at Johnson & Johnson Diagnostics, where she served as VP, strategic marketing as well as VP Europe, Mideast and Africa. 

Jan 03, 2019

Mike Guerra

California Life Sciences Association has appointed Mike Guerra as its CEO and president, effective January 7th. He will succeed Sara Radcliffe, who will be departing the firm to pursue new opportunities. Guerra previously served as VP of the Americas for Avidity Science. In addition, he has held senior leadership positions with VWR International over the last 14 years. His last role at VWR was VP of sales for the western region of the US. 

Jan 02, 2019

Steve Chapman, Robert Schueren, Matthew Rabinowitz

Natera has appointed Steve Chapman to CEO. He will take over from Matthew Rabinowitz, who will serve as executive chairman, effective Jan. 2, 2019. Chapman was previously the company's chief operating officer and Robert Schueren will replace Chapman as Natera's COO, effective Jan. 7, 2019. Schueren was most recently CEO of IntegenX, which was acquired by Thermo Fisher Scientific. Previously, he was general manager of genomics at Agilent Technologies and has also held various roles at Genentech.

Jan 02, 2019

Peter Meldrum

Myriad Genetics' former CEO Peter Meldrum passed away on Dec. 20, 2018, at the age of 71.


Meldrum co-founded Myriad in 1992 with Mark Skolnick, and led the company through many milestones, including its public offering in 1995, the launch of the flagship BRACAnalysis test, the acquisitions of Myriad RBM and Crescendo Bioscience, and the firm's expansion outside the US. By the time he retired in 2015, Myriad had grown to employ 2,500 people and had performed more than 2 million genetic tests.

After his retirement, Meldrum was the executive director of The Meldrum Foundation, his family's private charitable foundation that supports educational, artistic, and humanitarian programs. He was also chairman of the board of directors for Golden Pine Ventures, a biotech-focused venture capital firm.

Meldrum was born in 1947 in Salt Lake City, Utah. In 1970, he received his Bachelor of Science degree in chemical engineering from the University of Utah, and four years later received his MBA from the same institution. Westminster College awarded him an honorary Doctorate of Science in 2004 and the University of Utah gave him an honorary Doctorate of Engineering degree in 2009. Scientific American in 2002 selected him as one of the Top 50 Scientific Visionaries in the World.

Dec 26, 2018

Brad Wertz

Brad Wertz, chairman and founding investor of GenomOncology, will take over as CEO on Jan. 1, the Cleveland-based company announced. Manuel Glynias, GenomOncology's current CEO and founder, will remain president. Wertz has a history of scaling technology companies in various industries as they move from startup to growth phase, including bioinformatics software maker Acero. 

Dec 18, 2018

Jessica Hassel, Aurélien Marabelle

Protagen has appointed Jessica Hassel and Aurélien Marabelle to the firm's scientific advisory board. The members will support the company in developing and implementing its immuno-profiling technology. Hassel is currently the head of dermato-oncology at Germany's National Center for Tumor Disease. She has worked at the German Cancer Research Center Heidelberg, with a focus on translational oncology. Marabelle is currently the clinical director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. He works as a senior medical oncologist and an investigator in the center's drug development department. 

Dec 17, 2018

Amy Abernethy

Amy Abernethy, current chief medical officer, CSO, and senior VP of oncology at Flatiron Health, will join the US Food and Drug Administration as principal deputy commissioner, second to the agency's commissioner Scott Gottlieb. She is slated to join the agency in early 2019, pending ethics clearances, and will replace Rachel Sherman, who is retiring as the FDA's current principal deputy commissioner. Patrizia Cavazzoni, who is deputy director for operations at the FDA's drug center, will step in as interim principal deputy commissioner till Abernethy joins.

Abernethy became an executive at cancer-focused health technology firm Flatiron more than four years ago. She currently serves as a member of the board for CareDx, and will step down from that post effective Jan. 31, 2019. She has served as a director on the company's board since July 2018 as chairman of the scientific committee. Abernethy has also worked at Athenahealth and directed the Duke Center for Learning Health Care. In an internal email about Abernethy's hire, the FDA highlighted that she is an internationally recognized expert in clinical trials, cancer outcomes research, health policy, patient-reported outcomes, and patient-centered care, and has authored more than 400 peer-reviewed articles.

The non-profit advocacy organization Personalized Medicine Coalition, where Abernethy serves as a board member, noted in a statement that the agency's decision to hire her reflects its increasing focus on personalized medicine. While Abernethy was at Flatiron, the company struck up a research alliance with the FDA to explore how real-world data, derived from sources outside of the traditional clinical trial setting, could be used to gather evidence on the safety and efficacy of cancer treatments.

Dec 17, 2018

Richard Marsh, Benjamin Jackson

Richard Marsh, executive VP of Myriad Genetics, as well as its general counsel and secretary, will retire from the company effective July 1, 2019.  After serving as Myriad's general counsel for more than 16 years, Marsh has acceped the job of mission president for the Church of Jesus Christ of Latter-day Saints for the next three years.

Benjamin Jackson, currently Myriad's VP, assistant general counsel, and assistant secretary, will succeed Marsh. Jackson has been with the company since 2006 and has held positions dealing with commercial operations and intellectual property issues.

Dec 12, 2018

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Melissa Lueke, executive VP and CFO at Meridian Bioscience, will retire from her position effective Jan. 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of corporate development to the position of EVP, CFO, and principal financial officer, also effective Jan. 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior VP, Corporate Controller and Treasurer.

Dec 11, 2018

Catherine Friedman, Alex Aravanis

Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She has also held numerous executive positions during her investment banking career with Morgan Stanley, including as managing director and head of West Coast healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.

Grail has also appointed Alex Aravanis as CSO and head of R&D. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of R&D for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.

Dec 11, 2018

Hans Clevers

The board of directors of Roche Holding has proposed Hans Clevers as a new board member. He is scheduled to be elected to the board at the company's annual general meeting on March 5, 2019. Clevers is a professor of molecular genetics at the University Medical Center Utrecht in the Netherlands.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.